Exothera says it has successfully transferred IDT Biologika’s upstream process from small to large scale in the NevoLine Upstream platform (Univercells Technologies)
CDMOs IDT Biologika and Exothera are collaborating to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study will focus on Modified Vaccinia Ankara (MVA) virus as a first example for IDT’s vector technologies.
Exothera says it has successfully transferred IDT Biologika’s upstream process from small to large scale in the NevoLine Upstream platform (Univercells Technologies). The platform incorporates the scale-X structured fixed-bed bioreactor system which enables the scaling of viral production from R&D to commercialisation.
Romain de Rauville, VP Business Development at Exothera, said: “At Exothera we’re excited to be working collaboratively with IDT Biologika to leverage Univercells Technologies’ novel manufacturing platforms to design a high-quality, and cost-effective commercial process for the viral vector-based industry.”
Dr Simone Kardinahl, SVP Development at IDT Biologika, said: “Viral vaccines have been receiving special attention since the launch of COVID vaccines, however they had been important for many vaccine programs, in the past already. IDT Biologika has a strong track record in development and manufacturing of vaccine candidates; this is why our researchers are continuously looking for options to further optimise our processes in terms of quality and efficiency. The Univercells Technologies equipment is one further milestone on this path.”